logo-loader
ANGLE PLC

ANGLE PLC sees big opportunities in non-invasive prenatal testing

Andrew Newland, chief executive of ANGLE PLC (LON:AGL, OTCQX:ANPCY), tells Proactive London's Andrew Scott its device for detecting the early signs of cancer has shown promise harvesting fetal cells.

Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).

Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.

Quick facts: ANGLE PLC

Price: £0.81

Market: AIM
Market Cap: £139.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor update: ANGLE PLC sees head and neck cancer potential for its...

Headlines from the Proactive UK newsroom. ANGLE PLC (LON:AGL,OTCQX:ANPCY) says a review of its ground-breaking liquid biopsy has identified advantages to using the technology when treating head and neck cancer patients. The Parsortix system detects the tell-tale signs of cancer in the form of...

3 days, 3 hours ago

2 min read